Leadership Team

Has worked as CEO and entrepreneur in the IT service industry. Has supported for the pharmaceutical industry since the 1990s. Focuses on developing NDA as the undisputed global leader of strategic development advice, taking into account all critical commercial and regulatory considerations to successfully bring good medicines to patients in need.

Laurie has over 25 years of global leadership experience in the pharmaceutical and biotechnology industries in drug development, regulatory strategy and regulatory approvals across all major therapeutic areas. She has led the development and commercialization of drugs for oncology, HIV/AIDS, cardiovascular, metabolics, immunology, infectious diseases, neuroscience, dermatology, inflammatory and immune-based diseases.

Laurie has led numerous multidisciplinary teams in over 50 US FDA and European EMA proceedings, including preparations.

Seasoned healthcare executive with extensive industry experience and track record in the area of bio-pharmaceutical R&D strategy and operational management. Kurt joined NDA in April 2020, when he took over leadership of NDA’s advisory board.

Kurt brings extensive business acumen range from pre-clinical, clinical stages to the submission and approval of assets; he is familiar with scientific, medical, ethical, technical, regulatory and commercial success factors in life sciences.

Christine leads the commercial (business development & marketing) organization at NDA Group. Her passion over her 25+ years in and around life sciences is making an impact on patients' lives by helping bio/pharma companies be successful in achieving their missions.

She has strategic and operational experience in the healthcare sector broadly (bio/pharma, medtech, consumer, and services) both internally and as an advisor, with a proven track record of successful external business transactions, and team leadership and development.

Kim has 30 years of experience in global clinical and regulatory strategies for medicinal and aesthetic drugs and devices span all phases of development. Providing advice to clients on development and regulatory strategies and interactions with the FDA.  

Kim has extensive product development experience in multiple therapeutic areas including dermatology, respiratory, cardiovascular, hormone replacement, and autoimmune disorders.

Erica provides leadership development and management support to advance our NDA culture bringing out the best in our people.
Experienced in the employee lifecycle, team and individual development, organizational changes, implementation strategies and employee engagement.
Erica has 10 years experience in industry.

Thomas joined NDA as a strategic advisor in 2011 advising the company’s management and its clients on management and drug development strategies. He applies his skills to a broad range of regulatory and management areas and has successfully helped clients interact with regulatory agencies throughout the stages of development and during regulatory review.

Thomas was the Executive Director of the European Medicines Agency (EMA). He established the agency from a small unknown agency in 2001 to a world-renowned regulatory agency in 2011 and was responsible for all its operations. He previously served with the Swedish Medical Products Agency (MPA) as Director of Operations (1978-93) and Deputy Director-General, (Jan 93 – Dec 00).